Liquidia Corp
Research Liquidia Corp (LQDA) on Bullrun: market cap USD 6.27B, P/E 497.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLQDA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 6.27B
- P/E497.8
- Financial periodQ1 2026
- RevenueUSD 132.87M
- Net incomeUSD 22.31M
- Free cash flowUSD 50.16M
- Gross margin199.1%
Valuation Snapshot
latest market cap is USD 6.27B; P/E is 497.8.
Peer valuation comparison
Latest P/E is 497.81x versus a Healthcare sector median of 24.46x (1935.2% above).
Latest P/E is 497.81x versus a United States median of 24.87x (1902.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 158.32M | -USD 68.92M | -USD 40.02M | 91.6% | -0.8 | USD 190.68M | USD 197.93M | USD 44.75M |
| FY2024 | USD 14.00M | -USD 130.39M | -USD 98.37M | 58.0% | -1.63 | USD 176.48M | USD 120.29M | USD 79.38M |
| FY2023 | USD 17.49M | -USD 78.50M | -USD 42.85M | 83.5% | -1.21 | USD 83.68M | USD 49.54M | USD 47.29M |
| FY2022 | USD 15.94M | -USD 41.02M | -USD 29.18M | 82.1% | -0.67 | USD 93.28M | USD 19.88M | USD 90.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.27B | 497.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.01B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 995.87M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 824.50M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 410.83M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 254.64M | n/a | n/a | n/a |
About Liquidia Corp
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Liquidia Corp's market cap?
Liquidia Corp's market capitalization is USD 6.27B.
What is Liquidia Corp's P/E ratio?
Liquidia Corp's price-to-earnings (P/E) ratio is 497.8.
What does Liquidia Corp do?
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).